JMJavier Martínez-Blanco

Javier Martínez-Blanco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Javier Martínez-Blanco has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • A Echeverri

    Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional (GIRAT), School of Medicine, Universidad Icesi, and Fundación Valle del Lili, Cali, Colombia

    1 shared publication
  • Alex Echeverri

    Rheumatology Unit, Fundación Valle del Lili, ICESI University

    1 shared publication
  • Alexandra Cossio

    Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali, Colombia

    1 shared publication
  • C A Cañas

    Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional (GIRAT), School of Medicine, Universidad Icesi, and Fundación Valle del Lili, Cali, Colombia

    1 shared publication
  • Carlos A. Cañas

    Rheumatology Unit, Fundación Valle del Lili, ICESI University

    1 shared publication
  • D Aguirre-Valencia

    Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional (GIRAT), School of Medicine, Universidad Icesi, and Fundación Valle del Lili, Cali, Colombia

    1 shared publication

Latest Publications

  • Neutrophil CD64 expression, procalcitonin and presepsin are useful to differentiate infections from flares in SLE patients with SIRS

    by A Echeverri, J Naranjo-Escobar, I Posso-Osorio, D Aguirre-Valencia, D Zambrano, G L Castaño, J D Martínez, C A Cañas, G J Tobón

    Differentiating systemic lupus erythematosus (SLE) activity from infections in febrile patients is difficult because of similar initial clinical presentation. The aim of this study is to evaluate the usefulness of a number of biomarkers for differentiating infections from activity in SLE patients admitted with systemic inflammatory response (SIRS). Patients with SLE and SIRS admitted to the emergency room were included in this study. Measurements of different markers including procalcitonin, neutrophil CD64 expression and presepsin, were performed. Infection was considered present when positive cultures and/or polymerase chain reaction were obtained. Sensitivity and specificity were calculated for all biomarkers. Twenty-seven patients were admitted, 23 women (82.5%), mean age 33.2 years. An infectious disease was confirmed in 12 cases. Markers for SLE activity including anti-DNA titers by IIF (p = 0.041) and enzyme-linked immunosorbent assay (p = 0.009) were used for differentiating SLE flares from infection. On the contrary, increased procalcitonin (p = 0.047), neutrophil CD64 expression by flow cytometry (p = 0.037) and presepsin (p = 0.037) levels were observed in infected SLE patients. High neutrophil CD64 expression, presepsin and procalcitonin levels are useful to differentiate infections from activity in SLE patients. In most cases, a positive bioscore that includes these three markers demonstrate the presence of an infectious disease.


  • Distinguishing infectionsvsflares in patients with systemic lupus erythematosus: Table 1

    by Fabio E. Ospina, Alex Echeverri, Diana Zambrano, Juan-Pablo Suso, Javier Martínez-Blanco, Carlos A. Cañas, Gabriel J. Tobón

    SLE is a chronic autoimmune disease involving multiple systems. Patients with SLE are highly susceptible to infections due to the combined effects of their immunosuppressive therapy and the abnormalities of the immune system that the disease itself causes, which can increase mortality in these patients. The differentiation of SLE activity and infection in a febrile patient with SLE is extremely difficult. Activity indexes are useful to identify patients with lupus flares but some clinical and biological abnormalities may, however, make it difficult to differentiate flares from infection. Several biological markers are now recognized as potential tools to establish the difference between SLE activity and infection, including CRP and procalcitonin. It is possible, however, that the use of only one biomarker is not sufficient to confirm or discard infection. This means that new scores, which include different biomarkers, might represent a better solution for differentiating these two clinical pictures. This review article describes several markers that are currently used, or have the potential, to differentiate infection from SLE flares.


  • Exploratory analysis of preventable first day mortality in Colombia

    by M.C. Jaramillo-Mejía, D. Chernichovsky, J.D. Martínez-Blanco, J.J. Jiménez-Moleón


  • Open Access

    Clinical and Epidemiologic Profile of Cutaneous Leishmaniasis in Colombian Children: Considerations for Local Treatment

    by Victor M. Blanco, Alexandra Cossio, Javier D. Martinez, Nancy Gore Saravia

    Treatment alternatives have seldom been evaluated in children with cutaneous leishmaniasis (CL). We examine the clinical/epidemiological profile of children with CL considering international guidelines for local treatment. Descriptive analyses were conducted using International Center for Medical Research and Training (CIDEIM) case reports of parasitologically diagnosed patients ≤ 14 years of age from 2004 to 2010. Eligibility for local treatment based on World Health Organization/Pan American Health Organization (WHO/PAHO) criteria was determined. Among 380 children, 90% presented lesions of < 3 months duration, 54% presented single lesions < 30 mm in diameter, and 45% were ≤ 5 years old. Lesions on the head and neck were more frequent among children 0–5 years, and lesions below the head/neck were more frequent among 11- to 14-year-old children (P = 0.004). Using PAHO and WHO criteria, 26% and 53% of children, respectively, were eligible for local treatment. Recommended local treatments for New World CL have potential but limited applicability in children. Individual risk–benefit assessment and effectiveness data in children may increase eligibility.